GlassScriptPhysician profile
Sergey A Alentyev
NPI 1518366293
$2,358.64
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,377 · 2022: $220 · 2023: $591 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $606 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $605.67 |
| Education | $155.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $636.20 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $236.82 | 2021-2024 | Austedo |
| Sk Life Science, INC. | $174.84 | 2021-2023 | |
| Biogen, INC. | $108.44 | 2021-2023 | Vumerity, Avonex, Plegridy |
| Novartis Pharmaceuticals Corporation | $100.17 | 2021-2023 | |
| Abbott Laboratories | $91.63 | 2024 | Infinity |
| Lilly USA, LLC | $89.26 | 2021-2023 | Amyvid, Emgality, Reyvow |
| Biohaven Pharmaceuticals, INC. | $56.59 | 2021 | |
| Impel Pharmaceuticals INC. | $55.45 | 2023 | Trudhesa |
| Ucb, INC. | $54.10 | 2021-2023 | Briviact |
| Biohaven Pharmaceutical Holding Company LTD. | $51.74 | 2022 | |
| Amgen INC. | $46.84 | 2021 | |
| Allergan, INC. | $46.05 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $46.04 | 2021 | |
| Argenx US, INC. | $42.19 | 2022-2023 | Vyvgart, Vyvgart Hytrulo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $42.10 | 2021 | |
| Lundbeck LLC | $38.38 | 2023 | Vyepti |
| Neurocrine Biosciences, INC. | $37.85 | 2021-2023 | Ongentys, Ingrezza |
| Emd Serono, INC. | $37.73 | 2021 | |
| Pfizer INC. | $33.98 | 2023 | |
| Tanabe Pharma America, INC. | $32.18 | 2021 | |
| Mdd US Operations, LLC | $32.12 | 2021 | |
| Sunovion Pharmaceuticals INC. | $27.70 | 2021 | |
| Merck Sharp & Dohme LLC | $27.42 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.19 | 2022 | |
| Adamas Pharmaceuticals, INC. | $23.02 | 2021 | |
| Jazz Pharmaceuticals INC. | $22.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $21.47 | 2021 | |
| Livanova USA, INC. | $20.72 | 2021 | |
| Medtronic, INC. | $19.17 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.52 | 2021 | |
| Neurelis, INC. | $16.50 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.99 | 2021 | |
| Ge Healthcare | $14.81 | 2023 | |
| Celgene Corporation | $14.58 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Alentyev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.